Study finds HIV protease inhibitor drugs may adversely affect the scaffolding of the cell nucleus

Published in the July 16 early edition of Proceedings of the National Academy of Sciences, these biochemical findings may offer insights into the side effects of HIV protease inhibitors, including metabolic syndrome and regional losses of some of the body’s fat tissue. These side effects occur in up to one-third of patients taking anti-HIV drug regimens.

“We show, for the first time, that certain HIV protease inhibitor drugs directly inhibit an enzyme called ZMPSTE24, which is important for generating the structural scaffolding supporting the cell nucleus,” said Catherine Coffinier, Ph.D., study author and an assistant researcher at the David Geffen School of Medicine at UCLA.

UCLA researchers added HIV protease inhibitors to cultures of mouse and human fibroblast cells. They found that the inhibition of ZMPSTE24 by the HIV protease inhibitor drugs led to an accumulation of prelamin A, which is a precursor to mature lamin A — a key molecule in the structural scaffolding for the cell nucleus. ZMPSTE24 is a membrane-bound intracellular zinc metalloproteinase that is required for the conversion of prelamin A to mature lamin A.

Interestingly, researchers found that the accumulation of prelamin A was exaggerated in cells that contained half the normal amount of ZMPSTE24.

Genetic defects in ZMPSTE24 in humans lead to an accumulation of prelamin A and cause a host of disease phenotypes, including partial loss of body fat depots and metabolic syndrome.

“The fact that HIV protease inhibitors block ZMPSTE24 and have been associated with side effects similar to those observed with a genetic deficiency in ZMPSTE24 is intriguing,” said Loren Fong, Ph.D., study author and an associate professor of medicine at the David Geffen School of Medicine at UCLA.

The UCLA research team is known for its work on progeria, a precocious aging syndrome. Progeria syndromes can be caused by genetic defects that interfere with the conversion of prelamin A to lamin A.

“Since HIV protease inhibitors interfere with the conversion of prelamin A to lamin A, we believe — at least at a biochemical level — that there is a link between progeria syndromes and HIV treatment regimens,” Fong said.

There are many HIV protease inhibitors on the market. One of the next steps, according to Coffinier, is to determine whether the blocking of ZMPSTE24 activity and the accumulation of prelamin A is caused by every HIV protease inhibitor or only some of them.

All of the current studies were performed in cultured cells, not tissues from HIV-treated patients. In future studies, the UCLA team would like to assess the biochemical and pathological side effects of the HIV protease inhibitors in humans taking these medications.

“Ultimately, we would like to further explore why some HIV protease inhibitor-treated patients develop side effects while others do not,” said Dr. Stephen Young, study author and a professor of medicine at the David Geffen School of Medicine at UCLA.

The UCLA team was assisted by the laboratory of Christine Hrycyna, an associate professor of chemistry at Purdue University. The collaboration was a natural fit, as Hrycyna and the UCLA team share a common interest in ZMPSTE24 processing.

Source: University of California - Los Angeles

ABC-transporters expressed on endothelial cell membranes efflux anti-HIV drugs
Researchers at Tulane University Medical Center in New Orleans (USA) have discovered that drug-efflux pumps, belonging to the ATP-binding cassette (ABC) transporter family, are constitutively expressed on vascular endothelial cells. Transcripts for several different ABC-transporters, e.g. MDR-1 (P-gp) and MRPs, were detected in endothelial cells, obtained from brain, aortic artery, pulmonary artery, dermal microvessels and umbilical veins.
Since introduction of highly active antiretroviral therapy, HIV death rate has decreased
In industrialized countries, persons infected sexually with HIV now appear to experience mortality rates similar to those of the general population in the first 5 years following infection, though a higher risk of death remains as the duration of HIV infection lengthens, according to a study in the July 2 issue of JAMA.
Anti-HIV drugs reduce the cause of some forms of vision loss
A potential new therapeutic use for anti-HIV drugs known as protease inhibitors has been suggested by a team of researchers from Harvard Medical School, Boston, and Inserm U848, France, as a result of their work in a mouse model of retinal detachment.
Compound has potential for new class of AIDS drugs
Researchers have developed what they believe is the first new mechanism in nearly 20 years for inhibiting a common target used to treat all HIV patients, which could eventually lead to a new class of AIDS drugs.
Virtual human puts HIV drug to test
Harnessing the power of supercomputing, ‘grid’ technology and using a so-called ‘virtual physiological human’ (VPH), European researchers have simulated how well an HIV drug blocks a key protein in the lethal virus. The days of trial and error could be numbered.
Novel mathematical model predicts new wave of drug-resistant HIV infections in San Francisco
A mathematical model shows that a new wave of drug-resistant HIV is rising among among men in San Francisco who have sex with men and that this trend will continue over the next few years, according to a new study from the UCLA AIDS Institute.
Virtual human in HIV drug simulation
The combined supercomputing power of the UK and US ‘national grids’ has enabled UCL (University College London) scientists to simulate the efficacy of an HIV drug in blocking a key protein used by the lethal virus. The method – an early example of the Virtual Physiological Human in action – could one day be used to tailor personal drug treatments, for example for HIV patients developing resistance to their drugs.
Deadly virus strips away immune system's defensive measures
When the alert goes out that a virus has invaded the body, cells that have yet to be attacked prepare by "armoring" themselves for combat, attaching specific antiviral molecules to many of their own proteins to help resist the invader.

Study finds HIV protease inhibitor drugs may adversely affect the scaffolding of the cell nucleus

Related stories:

News discussion: